Krystal Biotech, Inc. · NASDAQ:KRYS
Krystal Biotech — Q3 2025 Earnings Presentation
15 slides from Krystal Biotech's earnings presentation, Nov 3, 2025
Slide 1: Third Quarter 2025 Financial and Operating Results
Third Quarter 2025 Financial and Operating Results November 3, 2025 © Copyright 2025 Krystal Biotech, Inc. All rights reserved.
Slide 2: Forward Looking Statements and Disclosures
Forward Looking Statements and Disclosures This presentation and our discussion contain forward-looking statements that involve substantial risks and uncertainties. Any statements about future expectations, plans, and prospects for Krystal Biotech, Inc. (together with its subsidiaries, the “Company”
Slide 3: 3Q Earnings Call Topics
3Q Earnings Call Topics ▪ U.S. and overseas VYJUVEK launch ▪ Near-term KB407 readout + pipeline progress ▪ Delivering top-line and bottom-line growth Krystal | 3
Slide 4: Over $623M in Net VYJUVEK Revenue Since Launch
Over $623M in Net VYJUVEK Revenue Since Launch US$ Millions $96.0 $97.8 $91.1 $88.2 $83.8 $70.3 $42.1 $45.3 $8.6 3Q 2023 4Q 2023 1Q 2024 2Q 2024 3Q 2024 4Q 2024 1Q 2025 2Q 2025 3Q 2025 Krystal | 4
Slide 5: Label Update and Approval Acceleration Support Growth Outlook in the U.S.
Label Update and Approval Acceleration Support Growth Outlook in the U.S. ▪ Sales force expansion has now driven two sequential quarters of reimbursement approval acceleration Over 615 ▪ Sales force training still underway with full impact Reimbursement Approvals expected in 2026 for VYJUVEK ▪ Label
Slide 6: Strong Start to European VYJUVEK Launch
Strong Start to European VYJUVEK Launch ✓ Launched in Germany in late August with widespread adoption and prescriptions from many key centers Early Germany Launch Metrics ✓ Approved for AP2 in France in September, launched in France in October* 20 Estimated DEB Patients with VYJUVEK Prescriptions Ov
Slide 7: Launch in Japan Now Underway
Launch in Japan Now Underway Over 500 Estimated DEB ▪ VYJUVEK approved by MHLW for the treatment of DEB Patients Across Japan patients from birth in July ▪ Pricing approved and VYJUVEK launched in October DEB, dystrophic epidermolysis bullosa; MHLW, Ministry of Health Labour and Welfare Krystal | 7
Slide 8: Building Specialty Distributor Partner Network for Rest of World Markets
Building Specialty Distributor Partner Network for Rest of World Markets ▪ Contracting with leading specialty distributors to support commercialization of VYJUVEK in rest of world ▪ Executed agreements in place for multiple markets ▪ Central and Eastern Europe ▪ Turkey ▪ Middle East ▪ Further expans
Slide 9: Platform Technology Designation Granted by FDA for KB801
Platform Technology Designation Granted by FDA for KB801 Potential Benefits of Designation KB801 ✓ Early and more frequent interactions with the FDA 2 x NGF genes ✓ Leveraging manufacturing and nonclinical safety data from a prior product such as VYJUVEK ✓ FDA may also consider previous inspectional
Slide 10: Rare Disease Pipeline Progressing with Near-Term Cystic Fibrosis Readout
Rare Disease Pipeline Progressing with Near-Term Cystic Fibrosis Readout Respiratory ▪ On track to report molecular data from KB407 Phase 1 for CF by year end ▪ Confirmed SERPINA1 gene delivery and safety of single dose KB408 this summer and now enrolling repeat dose cohort in KB408 Phase 1 for AATD
Slide 11: Narrowing Focus in Oncology to Inhaled KB707
Narrowing Focus in Oncology to Inhaled KB707 KB707 • Granted End of Phase 2 meeting by FDA to discuss inhaled KB707 Proprietary HSV-1 Vector development after early evidence of monotherapy activity in Encoding IL-2 and IL-12 advanced NSCLC patients from ongoing Phase 1/2 KYANITE-1 study • Aligned wi
Slide 12: KB111 Entering the Clinic for Treatment of Hailey-Hailey Disease
KB111 Entering the Clinic for Treatment of Hailey-Hailey Disease • Hailey-Hailey disease (HHD) is a rare genetic disease characterized by painful rash and blistering in skin folds • Prevalence not well characterized and may be underreported, estimated at 1 per 50,000 • HHD patients report high level
Slide 13: Third Quarter 2025 Financial Highlights
Third Quarter 2025 Financial Highlights Cash and investments: $864.2 million as of September 30, 2025 Diluted EPS: $2.66 Three Months Ended September 30 Nine Months Ended September 30 2025 2024 2025 2024 Product revenue, net $97.8M $83.8M $282.0M $199.4M Cost of goods sold $4.3M $6.7M $16.5M $15.1M
Slide 14: Strong Growth Trajectory from VYJUVEK and Pipeline
Strong Growth Trajectory from VYJUVEK and Pipeline ▪ VYJUVEK launch execution and geographic expansion ▪ Readouts from rare disease programs complementary to Krystal’s existing footprint ▪ KB407 Phase 1 for CF ▪ KB803 Phase 3 for corneal abrasions in DEB ▪ KB801 Phase 1/2 for NK ▪ Additional upside
Slide 15: Developing Genetic Medicines to Treat Diseases with High Unmet Medical Needs
Developing Genetic Medicines to Treat Diseases with High Unmet Medical Needs © Copyright 2025 Krystal Biotech, Inc. All rights reserved.